Innate Pharma (IPHA) Return on Equity (2020 - 2025)

Innate Pharma has reported Return on Equity for 6 years, with the latest figure at 0.11% in Q4 2025.

• For the quarter ending Q4 2025, Return on Equity rose 15.0% year-over-year to 0.11%; the trailing twelve-month figure through Dec 2025 stood at 0.11% (up 15.0% YoY), and the FY2022 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Equity for Q4 2025 stood at 0.11%, up from 0.15% in the prior quarter.
• The five-year high for Return on Equity was 0.11% in Q4 2025, with the low at 0.15% in Q2 2025.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2021.
• The largest YoY upside for Return on Equity was 15 bps in 2025 against a maximum downside of 14 bps in 2025.
• Innate Pharma's Return on Equity stood at 0.01% in 2021, then surged by 98 bps to 0.0% in 2022, then slumped by 583 bps to 0.0% in 2023, then plunged by 5690 bps to 0.04% in 2024, then jumped by 358 bps to 0.11% in 2025.
• The last three Return on Equity figures came in at 0.11% (Q4 2025), 0.15% (Q2 2025), and 0.04% (Q4 2024), per Business Quant data.